BioCryst Pharmaceuticals, Inc. $BCRX Stock Holdings Lowered by GW&K Investment Management LLC

GW&K Investment Management LLC cut its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 16.2% in the 3rd quarter, Holdings Channel reports. The firm owned 2,197,765 shares of the biotechnology company’s stock after selling 425,772 shares during the period. GW&K Investment Management LLC’s holdings in BioCryst Pharmaceuticals were worth $16,681,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its stake in BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of BioCryst Pharmaceuticals by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after purchasing an additional 8,517 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of BioCryst Pharmaceuticals by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock worth $14,490,000 after buying an additional 640,704 shares during the period. Caxton Associates LLP purchased a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in BioCryst Pharmaceuticals by 11.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock valued at $3,363,000 after buying an additional 47,355 shares during the period. 85.88% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on BCRX shares. Evercore started coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price objective on the stock. Weiss Ratings upgraded BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday. HC Wainwright increased their price objective on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Finally, Royal Bank Of Canada cut their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $19.64.

Insiders Place Their Bets

In related news, insider Alane P. Barnes sold 21,773 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $7.65, for a total transaction of $166,563.45. Following the completion of the transaction, the insider directly owned 398,751 shares of the company’s stock, valued at $3,050,445.15. This trade represents a 5.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.10% of the stock is owned by company insiders.

BioCryst Pharmaceuticals Stock Down 0.2%

BCRX stock opened at $8.48 on Friday. The business’s 50-day simple moving average is $7.23 and its 200 day simple moving average is $7.41. The company has a market cap of $2.13 billion, a PE ratio of 7.07 and a beta of 0.74. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.07 by $1.05. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The firm had revenue of $163.28 million during the quarter, compared to analysts’ expectations of $151.32 million. During the same period last year, the business earned ($0.13) earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 209.1% compared to the same quarter last year. On average, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.